127 related articles for article (PubMed ID: 25110082)
1. On statistical relationship between ADRA2A expression and the risk of breast cancer relapse.
Shkurnikov MY; Galatenko VV; Lebedev AE; Podol'skii VE; Tonevitskii EA; Mal'tseva DV
Bull Exp Biol Med; 2014 Aug; 157(4):454-8. PubMed ID: 25110082
[TBL] [Abstract][Full Text] [Related]
2. ADRA2A Germline Gene Polymorphism is Associated to the Severity, but not to the Risk, of Breast Cancer.
Kaabi B; Belaaloui G; Benbrahim W; Hamizi K; Sadelaoud M; Toumi W; Bounecer H
Pathol Oncol Res; 2016 Apr; 22(2):357-65. PubMed ID: 26563278
[TBL] [Abstract][Full Text] [Related]
3. Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.
Brown DN; Caffa I; Cirmena G; Piras D; Garuti A; Gallo M; Alberti S; Nencioni A; Ballestrero A; Zoppoli G
Sci Rep; 2016 Jan; 6():19435. PubMed ID: 26777065
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of α- and β2-adrenoceptor gene expression in breast cancer patients.
Rivero EM; Martinez LM; Bruque CD; Gargiulo L; Bruzzone A; Lüthy IA
Br J Clin Pharmacol; 2019 Sep; 85(9):2143-2154. PubMed ID: 31218733
[TBL] [Abstract][Full Text] [Related]
5. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
7. Stable Gene Signature Selection for Prediction of Breast Cancer Recurrence Using Joint Mutual Information.
Sehhati M; Mehridehnavi A; Rabbani H; Pourhossein M
IEEE/ACM Trans Comput Biol Bioinform; 2015; 12(6):1440-8. PubMed ID: 26671813
[TBL] [Abstract][Full Text] [Related]
8. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
9. Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach.
Sun Y; Urquidi V; Goodison S
Breast Cancer Res Treat; 2010 Feb; 119(3):593-9. PubMed ID: 19291396
[TBL] [Abstract][Full Text] [Related]
10. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
[TBL] [Abstract][Full Text] [Related]
11. Critical review of microarray-based prognostic tests and trials in breast cancer.
Koscielny S
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):47-50. PubMed ID: 18197005
[TBL] [Abstract][Full Text] [Related]
12. Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
Gage MM; Mylander WC; Rosman M; Fujii T; Le Du F; Raghavendra A; Sinha AK; Espinosa Fernandez JR; James A; Ueno NT; Tafra L; Jackson RS
Ann Oncol; 2018 May; 29(5):1280-1285. PubMed ID: 29788166
[TBL] [Abstract][Full Text] [Related]
13. Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.
de Ruijter TC; van der Heide F; Smits KM; Aarts MJ; van Engeland M; Heijnen VCG
Breast Cancer Res; 2020 Jan; 22(1):13. PubMed ID: 32005275
[TBL] [Abstract][Full Text] [Related]
14. Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Tiirikainen M; Yu H
FEBS Open Bio; 2019 Jul; 9(7):1270-1280. PubMed ID: 31102318
[TBL] [Abstract][Full Text] [Related]
15. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
16. Estimating the OncotypeDX score: validation of an inexpensive estimation tool.
Eaton AA; Pesce CE; Murphy JO; Stempel MM; Patil SM; Brogi E; Hudis CA; El-Tamer M
Breast Cancer Res Treat; 2017 Feb; 161(3):435-441. PubMed ID: 27928699
[TBL] [Abstract][Full Text] [Related]
17. Improved breast cancer prognosis through the combination of clinical and genetic markers.
Sun Y; Goodison S; Li J; Liu L; Farmerie W
Bioinformatics; 2007 Jan; 23(1):30-7. PubMed ID: 17130137
[TBL] [Abstract][Full Text] [Related]
18. New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women.
Poorhosseini SM; Hashemi M; Alipour Olyaei N; Izadi A; Moslemi E; Ravesh Z; Hashemi-Gorji F; Kheiri HR; Yassaee VR
Asian Pac J Cancer Prev; 2016; 17(S3):155-60. PubMed ID: 27165221
[TBL] [Abstract][Full Text] [Related]
19. Predicting OncoDx recurrence scores with immunohistochemical markers.
Bradshaw SH; Pidutti D; Gravel DH; Song X; Marginean EC; Robertson SJ
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):490-6. PubMed ID: 23455176
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive factors and genetic analysis of early breast cancer.
Martín M; González Palacios F; Cortés J; de la Haba J; Schneider J
Clin Transl Oncol; 2009 Oct; 11(10):634-42. PubMed ID: 19828405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
